Healthcare Industry News: Ventana
News Release - October 8, 2008
Pathwork Diagnostics Announces Key Additions to Management TeamCFO and VP of US Sales Bring Industry Expertise to Pathwork Following FDA Clearance and $20M Fundraising Round
SUNNYVALE, Calif., Oct. 8 -- (Healthcare Sales & Marketing Network) -- Pathwork Diagnostics, a molecular diagnostics company focused on oncology, announced today the appointment of two key positions within the company's management team, Fletcher Payne as Chief Financial Officer and Mark McDonough as Vice President of US Sales. These professionals bring over 20 years of industry expertise in their respective positions to Pathwork.
"Having Fletcher and Mark on the Pathwork management team will be a great asset moving forward," said Deborah J. Neff, President and Chief Executive Officer of Pathwork Diagnostics. "Both have proven track records in helping emerging companies grow efficiently and achieve results."
Pathwork's new CFO, Fletcher Payne, a graduate of UC Berkeley's Haas School of Business with a BS in Business Administration, joins Pathwork from Plexxikon Inc., a biopharmaceutical company where he served as a VP and CFO. Payne will lead the financial team, implement processes to support commercial growth and develop the overall financial strategy. Payne has over 20 years of business and financial experience, in both start-up and Fortune 500 companies. Prior to Plexxikon, he worked for Rinat Neuroscience, Dynavax Technologies, Cell Genesys, Sun Microsystems and IBM.
Mark McDonough joins Pathwork as Vice President of US Sales from US LABS, a division of Laboratory Corporation of America. With over 10 years of cancer diagnostics and reference laboratory experience, Mark will be responsible for the strategic and tactical sales initiatives at Pathwork. Prior to his time at US LABS, McDonough held various sales and sales management roles at Ventana Medical Systems and served as a Navigator and Communications Officer in the United States Navy. McDonough is a graduate of Miami University of Ohio with a BS in Finance.
About Pathwork Diagnostics
Pathwork Diagnostics, Inc., based in Sunnyvale, Calif., develops and commercializes high-value molecular diagnostics for oncology. The company's first test to market -- the Pathwork® Tissue of Origin Test -- utilizes proprietary analytics and a companion Pathchip® microarray, which runs on the proven Affymetrix GeneChip® System. The test aids in determining a hard-to-identify tumor's origin so that standard-of-care, cancer-specific treatment can begin. The test is FDA-cleared as an in vitro diagnostic kit, while a functionally equivalent version of the test is also available through the CLIA-certified Pathwork® Diagnostics Laboratory. For more information, call 1.877.808.0006 or visit http://www.pathworkdx.com.
Pathwork, Pathchip, Pathwork Diagnostics, and the Pathwork Diagnostics logo are trademarks or registered trademarks of Pathwork Diagnostics, Inc. Other names may be the trademarks of their respective owners.
Source: Pathwork Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.